treatment 2 at day 6
We developed a BAdV vector platform and demonstrated its utility in eluding an exceptionally high level of vector immunity in a mouse model. We found that immunizing mice with BAd-H5HA led to much stronger humoral (including mucosal) and CMI responses at a lower vector dose. This meant that the mice were completely protected when they were challenged with a different influenza virus than the HAd-H5HA-immunized group. Better immune responses to BAd-H5HA were seen when the vaccine was given intramuscularly (IM). However, a 30-fold higher dose of the vaccine provided full protection.